...
首页> 外文期刊>BMC Cancer >Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer
【24h】

Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer

机译:通过抑制EGFR / Akt / p38 / ERK信号通路和非小细胞肺癌中PARP-1抑制作用增强碳离子暴露后上皮-间质转化来降低转移潜能

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Carbon ion (12C) radiotherapy is becoming very promising to kill highly metastatic cancer cells keeping adjacent normal cells least affected. Our previous study shows that combined PARP-1 inhibition with 12C ion reduces MMP-2,-9 synergistically in HeLa cells but detailed mechanism are not clear. To understand this mechanism and the rationale of using PARP-1 inhibitor with 12C ion radiotherapy for better outcome in controlling metastasis, we investigated metastatic potential in two non-small cell lung cancer (NSCLC) A549 and H1299 (p53-deficient) cells exposed with 12C ion in presence and absence of PARP-1 inhibition using siRNA or olaparib. We monitored cell proliferation, in-vitro cell migration, wound healing, expression and activity of MMP-2, ??9 in A549 and p53-deficient H1299 cell lines exposed with 12C ion with and without PARP-1 inhibitor olaparib/DPQ. Expression and phosphorylation of NF-kB, EGFR, Akt, p38, ERK was also observed in A549 and H1299 cells exposed with 12C ion with and without PARP-1 inhibition using siRNA or olaparib. We also checked expression of few marker genes involved in epithelial-mesenchymal transition (EMT) pathways like N-cadherin, vimentin, anillin, claudin-1, ??2 in both NSCLC. To determine the generalized effect of 12C ion and olaparib in inhibition of cell’s metastatic potential, wound healing and activity of MMP-2, ??9 was also studied in HeLa and MCF7 cell lines after 12C ion exposure and in combination with PARP-1 inhibitor olaparib. Our experiments show that 12C ion and PARP-1 inhibition separately reduces cell proliferation, cell migration, wound healing, phosphorylation of EGFR, Akt, p38, ERK resulting inactivation of NF-kB. Combined treatment abolishes NF-kB expression and hence synergistically reduces MMP-2, ??9 expressions. Each single treatment reduces N-cadherin, vimentin, anillin but increases claudin-1, ??2 leading to suppression of EMT process. However, combined treatment synergistically alters these proteins to suppress EMT pathways significantly. The activation pathways of transcription of MMP-2,-9 via NF-kB and key marker proteins in EMT pathways are targeted by both 12C ion and olaparib/siRNA. Hence, 12C ion radiotherapy could potentially be combined with olaparib as chemotherapeutic agent for better control of cancer metastasis.
机译:碳离子(12C)放射疗法正在变得非常有希望杀死高转移性癌细胞,使相邻正常细胞受到的影响最小。我们以前的研究表明,结合PARP-1抑制和12C离子可在HeLa细胞中协同降低MMP-2,-9,但具体机制尚不清楚。为了了解这种机制以及在12C离子放射治疗中使用PARP-1抑制剂以更好地控制转移的原理,我们研究了两种非小细胞肺癌(NSCLC)A549和H1299(p53缺陷型)细胞暴露于非小细胞肺癌的转移潜力。使用siRNA或olaparib抑制和抑制PARP-1时的12C离子。我们监测了在有和没有PARP-1抑制剂olaparib / DPQ的12C离子暴露的A549和p53缺陷型H1299细胞系中的细胞增殖,体外细胞迁移,伤口愈合,MMP-2,Δ9的表达和活性。在暴露于12C离子的A549和H1299细胞中,使用siRNA或olaparib抑制和不抑制PARP-1,也观察到NF-kB,EGFR,Akt,p38,ERK的表达和磷酸化。我们还检查了两个NSCLC中参与上皮-间质转化(EMT)途径的少数标志物基因的表达,如N-钙粘着蛋白,波形蛋白,阿尼林,claudin-1,?2。为了确定12C离子和olaparib在抑制细胞转移潜力,伤口愈合和MMP-2活性方面的普遍作用,还研究了在12C离子暴露后与PARP-1抑制剂联合作用于HeLa和MCF7细胞系中的?? 9。奥拉帕尼。我们的实验表明12C离子和PARP-1抑制分别降低细胞增殖,细胞迁移,伤口愈合,EGFR,Akt,p38,ERK的磷酸化,从而导致NF-kB失活。联合治疗消除了NF-kB的表达,因此协同降低了MMP-2,Δ9的表达。每种单独的治疗方法均会减少N-钙黏着蛋白,波形蛋白,阿尼林,但会增加claudin-1,α2,从而抑制EMT过程。但是,联合治疗可以协同改变这些蛋白质,从而显着抑制EMT途径。通过12C离子和olaparib / siRNA靶向EMT途径中MMP-2,-9通过NF-kB和关键标记蛋白的转录激活途径。因此,12C离子放射疗法可能会与olaparib作为化疗药物联合使用,以更好地控制癌症转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号